Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin vs. Vancomycin for MRSA Bacteremia
NCT06637332Phase 4Recruiting
- Start
- Nov 2024
- Primary completion
- Jan 2029
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of daptomycin in Staphylococcus aureus bacteremia (SAB) (2 arms). Primary endpoint: Desirability of Outcome Ranking at 90 days. Started Nov 2024; status: recruiting.
02
Drugs
daptomycin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT06637332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637332.